



Review

Targeting Angiogenesis in Prostate Cancer

Zsombor Melegh ¹ and Sebastian Oltean ^{2,*}

¹ Department of Cellular Pathology, Southmead Hospital, Bristol BS10 5NB, UK; zsombor.melegh@nbt.nhs.uk

² Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter EX12LU, UK

* Correspondence: s.oltean@exeter.ac.uk

Received: 7 May 2019; Accepted: 29 May 2019; Published: 31 May 2019



Abstract: Prostate cancer is the most commonly diagnosed cancer among men in the Western world. Although localized disease can be effectively treated with established surgical and radiopharmaceutical treatments options, the prognosis of castration-resistant advanced prostate cancer is still disappointing. The objective of this study was to review the role of angiogenesis in prostate cancer and to investigate the effectiveness of anti-angiogenic therapies. A literature search of clinical trials testing the efficacy of anti-angiogenic therapy in prostate cancer was performed using Pubmed. Surrogate markers of angiogenic activity (microvessel density and vascular endothelial growth factor A (VEGF-A) expression) were found to be associated with tumor grade, metastasis, and prognosis. Six randomized studies were included in this review: two phase II trials on localized and hormone-sensitive disease ($n = 60$ and 99 patients) and four phase III trials on castration-resistant refractory disease ($n = 873$ to 1224 patients). Although the phase II trials showed improved relapse-free survival and stabilisation of the disease, the phase III trials found increased toxicity and no significant improvement in overall survival. Although angiogenesis appears to have an important role in prostate cancer, the results of anti-angiogenic therapy in castration-resistant refractory disease have hitherto been disappointing. There are various possible explanations for this lack of efficacy in castration-resistant refractory disease: redundancy of angiogenic pathways, molecular heterogeneity of the disease, loss of tumor suppressor protein phosphatase and tensin homolog (PTEN) expression as well as various VEGF-A splicing isoforms with pro- and anti-angiogenic activity. A better understanding of the molecular mechanisms of angiogenesis may help to develop effective anti-angiogenic therapy in prostate cancer.

Keywords: prostate cancer; angiogenesis; VEGF-A; splicing isoforms

1. Introduction

Prostate cancer is the most commonly diagnosed cancer in men in the Western world, with a median age at diagnosis of 66 years [1]. There will be an estimated 160,000 new cases and 30,000 deaths in 2018 in the USA, representing 19% of all new cancer diagnoses and 9% of all cancer related deaths, respectively [2]. In the United Kingdom, over 47,000 men are diagnosed with prostate cancer every year, with over 330,000 men currently living with the disease [3]. The purpose of this literature review is to assess whether angiogenesis is important in prostate cancer and, if so, whether anti-angiogenic therapies are effective in the treatment of prostate cancer. To begin with, the current treatment options in prostate cancer will be discussed, along with a summary of what is already known in relation to angiogenesis in cancer. This will be followed by the literature review on angiogenesis and anti-angiogenic therapies in prostate cancer, specifically. Finally, the discussion will consider any treatment difficulties that have emerged in such studies.

2. Background

2.1. Prostate Cancer

Prostate cancer is characterized by slow to moderate growth. Consequently, many cases are indolent and in up to 70% of incidentally diagnosed cases over 60 years death is due to an unrelated cause [4]. The five-year relative survival rate for men diagnosed in the USA between 2001 and 2007 with local or regional disease was 100%, whilst the rate for distant disease was 28.7% [5]. UK statistics show similar results: the five-year relative survival for prostate cancer was 100% in localized disease and 30% in distant disease for patients diagnosed during 2002–2006 in the former Anglia Cancer Network [6]. Most cases of prostate cancer are diagnosed by prostate specific antigen (PSA) testing or rarely by rectal examination. Prostate cancer can present with decreased urinary stream, urgency, hesitancy, nocturia, or incomplete bladder emptying, but these symptoms are non-specific and are infrequent at diagnosis [7].

2.2. Treatment Options in Prostate Cancer

Prostate cancer staging is divided into four stages. Stage 1 and 2 cancers are localized to the prostate whilst stage 3 cancers extend into the periprostatic tissue or the seminal vesicle, without involvement of a nearby organ or lymph node and with no distant metastasis [8]. Stage 4 tumors represent those that have spread to nearby or distant organs or lymph nodes [8].

Stage 1 tumors and stage 2 tumors of low and intermediate risk (Table 1) can be followed up by ‘watchful waiting’ or active surveillance and monitoring [9,10]. Watchful waiting has no curative intent, whilst active surveillance and monitoring defers treatment with curative intent to a time when it is needed [9]. Therefore, in active surveillance and monitoring therapy is reserved for tumor progression, with a 1–10% mortality rate [9].

Table 1. Risk stratification of localized prostate cancer according to NICE guidance, UK [10]. Gleason score: histological pattern of the tumor. Stage T1–T2a: tumor involving <50% of one lobe. Stage T2b: tumor involving ≥50% of one lobe. Stage T2c: tumor involving both lobes. NICE stands for the National Institute for Health and Care Excellence. PSA stands for Prostate-Specific Antigen.

Level of Risk	PSA Level (ng/mL)		Gleason Score		Clinical Stage
Low risk	<10	<i>and</i>	≤6	<i>and</i>	T1–T2a
Intermediate risk	10–20	<i>or</i>	7	<i>or</i>	T2b
High risk	>20	<i>or</i>	8–10	<i>or</i>	≥T2c

Radical prostatectomy is a treatment option for localized tumors in patients with few comorbidities. Although this provides an improvement in disease progression compared to active surveillance and monitoring, it does not translate into a statistical difference in mortality: 10-year cancer-specific survival rates were 98.8% with active surveillance and monitoring compared to 99% with radical prostatectomy [9]. Complications of radical prostatectomy include the mortality and morbidity associated with major surgery and anaesthesia, penile shortening, impotence, urinary and faecal incontinence, and inguinal hernia [8].

Radiation and radiopharmaceutical treatment options include external-beam radiation therapy (EBRT), interstitial implantation of radioisotopes into the prostate and hormonal manipulation [9]. EBRT is used with curative intent in all stages of prostate cancer, with or without adjuvant hormonal therapy. Interstitial implantation of radioisotopes is used in patient with stage 1 and 2 tumors. Short term results are similar to those seen with EBRT or radical prostatectomy, but the maintenance of sexual potency is significantly higher (86–96%) when compared to radical prostatectomy or EBRT (10–40% and 40–60%, respectively) [11].

Hormonal manipulation options include surgical castration (orchidectomy) or medical castration (LH-RH antagonists) [12]. These may be used in stage 3 or 4 cancers and can be enhanced by the addition of anti-androgenic therapy and adjuvant treatment with bisphosphonates [13]. Recently approved anti-androgen agents include abiraterone acetate, an inhibitor of cytochrome P450c17, a critical enzyme in androgen synthesis and enzalutamide, a second generation androgen-receptor–signaling inhibitor [13–15].

Treatment options for high stage metastatic hormone-refractory prostate cancer include active cellular immunotherapy with sipuleucel-T, which has resulted in increased overall survival in metastatic castration-resistant prostate cancer, in a double-blind, placebo-controlled, multicenter phase 3 trial [16]. This led to its approval for the treatment of asymptomatic or minimally symptomatic patients with nonvisceral metastatic castration-resistant prostate cancer in 2010. Radium-223 dichloride is used in symptomatic patients with bone metastases and no known visceral metastases [17]. Cabazitaxel, a derivative of docetaxel, is approved as a second line chemotherapy agent [18]. Further possible treatment options to prevent bone metastases include denosumab (a monoclonal antibody that inhibits osteoclast function) [19] and bone-seeking radionucleotides (strontium chloride Sr 89) [20].

Despite a widening arsenal of new treatment options, a cure is rarely achieved in stage 4 prostate cancer, although there is a striking difference in treatment response between individual patients [21]. Such outcomes emphasize the need for research into further treatment options in hormone-refractory advanced prostate cancer. One such emerging therapeutic option is inhibition of tumor-related angiogenesis.

2.3. Angiogenesis in Cancer

Angiogenesis is defined as the development of new vascular vessels from pre-existing blood vessels. It has a critical role in wound healing and embryonic development and also provides collateral formation for improved organ perfusion in ischaemia [22]. It is a multi-step process triggered by an angiogenic stimulus (Figure 1). The first step of the process is the production of proteases which degrade the basement membrane. This is followed by migration and proliferation of the endothelium, resulting in the formation of a new vascular channel [23].




Figure 1. Angiogenesis in cancer. Hypoxia within the tumor induces the release of pro-angiogenic factors and results in degradation of the basement membrane by matrix metalloproteinases (MMP). The endothelial cells start to differentiate and proliferate, forming new blood vessels. The newly formed blood vessels allow further tumor growth.

Although angiogenesis is not entirely necessary for tumor initialization (some tumors of the brain, lung, and liver can grow along pre-existing vessels) [23], once a tumor reaches a size of more than a few millimeters, formation of new blood vessels is necessary to provide an appropriate blood supply to support tumor cell viability and proliferation. Hence, angiogenesis plays an important role in tumor progression and is now recognized as one of the hallmarks of cancer [24].

Angiogenesis is controlled by a delicate balance between angiogenesis inducers and angiogenesis inhibitors. In a growing cancer there is a constant production of angiogenesis inducers, including vascular endothelial growth factor (VEGF)-A, basic fibroblast growth factor (bFGF, also known as FGF), angiogenin, tumor necrosis factor (TNF)- α , granulocyte colony-stimulating factor (G-CSF), platelet-derived endothelial growth factor (PDGF), placental growth factor (PGF), transforming growth factor (TGF)- α , TGF- β , interleukin-8 (IL-8), hepatocyte growth factor (HGF), and epidermal growth factor (EGF) [22]. This constant production of angiogenesis inducers results in increased activity of endothelial cells, as long as the production of anti-angiogenic factors is correspondingly reduced [25]. Among the angiogenesis activators, VEGF-A and bFGF are particularly important in tumor angiogenesis. The abundance and redundant activities of different angiogenesis inducers may explain the resistance or suboptimal effectiveness of anti-angiogenic therapies, when inhibitors acting only on a single angiogenesis activator are being used [25].

Under normal conditions, angiogenesis inducers are balanced by naturally occurring angiogenesis inhibitors, such as endostatin, angiostatin, IL-1, IL-12, interferons, metalloproteinase inhibitors, and retinoic acid [25,26]. These inhibitors can either disrupt new vessel formations or can help to remove already formed vascular channels. Shifting the balance towards angiogenesis inhibition can interfere with important physiological roles of angiogenesis, such as in embryo development, wound healing, and renal function. Interference with wound healing is a particularly important concern in cancer treatment, for example resulting in delayed post-operative healing [27]. Another example involves the inhibition of VEGF-A, resulting in vasoconstriction by means of elevated NO production, consequently elevating blood pressure [28], and increasing the risk of thrombogenesis, resulting in stroke or myocardial infarction. These factors can potentially limit the use of angiogenesis inhibition in cancer, on account of their potential side effects.

2.4. Angiogenesis Inhibition in Cancer

Although angiogenesis is an essential factor in tumor progression, by means of new vessel formation, this also means that angiogenesis inhibition may only result in inhibition of further tumor growth and may not actively eliminate the tumor. This, and the redundancy of the numerous angiogenesis inducers as listed above, explain why the utilization of angiogenesis inhibitors as a monotherapy has not proved to be as effective as initially expected [29]. Hence, angiogenesis inhibitor therapeutic regimes may require a combination of several anti-angiogenic strategies or may need to be complemented by other non-angiogenesis related chemotherapeutic agents in order to achieve an optimal therapeutic effect [30].

Based on the target of the therapeutic agent, angiogenesis inhibition can be divided into two main groups: direct and indirect inhibition [31]. Direct inhibitors target growing endothelial cells, whilst indirect inhibitors target the tumor cells or tumor-associated stromal cells. Small molecular fragments (e.g., arrestin, tumstatin, canstatin, endostatin, and angiostatin) are the products of proteolytic degradation of the extracellular matrix, and act as direct inhibitors by means of inhibition of the endothelial cell proliferation and migration induced by VEGF-A, bFGF, PDGF, and interleukins [32]. The direct anti-angiogenic effect of targeting integrins (cellular adhesion receptors), has also been demonstrated [32]; an integrin inhibitor—cilentigide—has been shown to inhibit tumor cell invasion [33]. Unfortunately, even though cilentigide acts both on tumor cells and endothelial cells and could be a prime example of multifactorial treatment, results of clinical trials have proved disappointing so far [34].

The most extensively clinically used direct anti-angiogenic strategy targets VEGF-A or its receptors. VEGF-A binds to its receptors to stimulate the proliferation of endothelial cells via the RAS–RAF–MAPK (mitogen-activated protein kinase) signalling pathway [35]. Bevacizumab is a humanised IgG1 monoclonal antibody against VEGF-A. It selectively binds to circulating VEGF-A, preventing its interaction with its receptor, VEGF-receptor 2, expressed on the surface of endothelial cells. Initial studies showed clinical improvement when bevacizumab was used in combination with chemotherapy in a number of cancers, without a marked increase in toxicity [36]. Subsequently it has been approved as part of a combination therapy in the treatment of various cancers, including metastatic lung,

colorectal, and renal cell carcinoma, and as a single agent treatment in adult glioblastoma [37]. However, subsequent studies have revealed adverse effects, including gastrointestinal perforation, nephrotic syndrome, thromboembolism, surgical wound healing complications and hypertension [37,38].

In contrast, indirect angiogenesis inhibition involves an interplay between tumor or stromal cells and angiogenesis. One example involves the inhibition of epidermal growth factor receptor (EGFR), a tyrosine kinase receptor. Tumor cell expression and activation of EGFR induces interleukin production, which is demonstrated to promote intratumoral angiogenesis. Thus, blocking the expression and/or activity of EGFR can result in indirect inhibition of angiogenesis [39].

To summarize, a number of anti-angiogenesis drugs have already been approved and are currently used in cancer treatment. This prompts the question whether angiogenesis plays any role in prostate cancer progression and, if so, whether anti-angiogenic therapy would be effective in refractory castration-resistant prostate cancer, for which the current treatment options are limited.

3. Results

3.1. Angiogenesis in Prostate Cancer

Currently there are no direct markers to assess angiogenic activity in prostate cancer, but it is reasonable to assume that vascular density is an indicator of intratumoral angiogenic activity. Microvessel density (MVD) is considered a good surrogate marker of angiogenic activity and has been demonstrated as a prognostic factor in various tumors, including breast and colon cancers as well as malignant melanoma [40]. MVD can be assessed by histological examination of the vasculature, either by assessing the most vascularised area of the tumor ('hot spot') or a random representative area. Preliminary data suggested that MVD is associated with higher tumor grade and stage, and worse outcome in prostate cancer [41,42]. Moreover, ultrasound imaging studies of haemodynamic indices have shown a higher peak intensity in high-grade tumors [43]. Later studies, however, have failed to confirm that MVD is an independent prognostic factor in untreated tumors, and no correlation has yet been established between MVD and effectiveness of anti-angiogenic treatment in prostate cancer [44]. Reasons for these conflicting results potentially include different counting methods, differences in antibodies used, different population sizes, personal experience and pathological background [45]. A further limiting factor is the complex geometrical structure of the newly formed vascular system, which is difficult to analyse on a two dimensional histological section [46]. Fractal geometry to estimate the surface dimension, computer aided automated image analysis, 3D models or magnetic resonance imaging could potentially be used to overcome these shortcomings, [46,47].

Another possible surrogate marker for tumor angiogenesis is by an assessment of the level of angiogenic regulators in the tumor. Both physiological and pathological angiogenesis is predominantly regulated by VEGF, which has various protein isoforms, each acting on their specific tyrosine kinase receptor at the cell surface [48]. Among the VEGF isoforms, VEGF-A has been extensively studied, and it has been demonstrated to play an important role in prostate cancer angiogenesis [49]. In addition, VEGF-A has been found to be overexpressed in prostate cancer and a high level of VEGF-A is associated with distant metastasis and a poorer prognosis [50–52]. Furthermore, in prostate cancer a high-level VEGF-A expression has been found not only in endothelial cells, but also in tumor cells [53].

These findings suggest that angiogenesis is important in prostate cancer, prompting subsequent clinical studies to assess whether anti-angiogenesis therapy is effective in the treatment of prostate cancer.

3.2. Anti-Angiogenesis Clinical Studies in Prostate Cancer

An unfiltered Pubmed search for the keywords "angiogenesis" and "prostate" revealed a steady increase in published papers between 2000 and 2013 (from 70 per year in 2000 to 213 per year in 2013) followed by a slow decline (down to 115 in 2018). This appears to reflect the fact that, despite the promising findings of initial studies, suggesting an important role of angiogenesis in prostate cancer, phase III clinical trials, mainly conducted after 2010, have proved disappointing so far.

Since VEGF-A was demonstrated to be overexpressed in prostate cancer and associated with poor prognosis and metastasis, most anti-angiogenic clinical studies in prostate cancer have targeted VEGF-A. A randomized phase II trial on bevacizumab involving 99 patients with hormone-sensitive prostate cancer showed improved relapse-free survival when bevacizumab was used alongside hormone-deprivation therapy (Table 2) [54]. A randomized, double-blind, placebo-controlled phase III clinical study of 1050 patients with prostate cancer showed some improvement in progression-free survival, but found no significant improvement in overall survival in metastatic, castration-resistant prostate cancer, when bevacizumab was used together with docetaxel chemotherapy and prednisone hormonal therapy [55]. Furthermore, bevacizumab resulted in increased toxicity and a greater incidence of treatment-related deaths [55]. This suggests that bevacizumab has some positive effect, especially on hormone-sensitive recurrent prostate cancer, but in hormone-resistant refractory tumors, in which the conventional treatment options are particularly prone to failure, adding bevacizumab treatment does not have any clinical benefit (Table 2).

Table 2. Anti-angiogenesis clinical studies in treatment of prostate cancer.

Drug	Mechanism of Action	Phase of the Clinical Trial	Number of Patients	Outcome
Bevacizumab	Recombinant humanized monoclonal antibody that blocks VEGF-A	II	99	Improved relapse-free survival [54]
		III	1050	No improvement in overall survival [55]
Aflibercept	Binds to circulating VEGF-A	III	1224	No improvement in overall survival [56]
Sunitinib	Receptor tyrosine kinase inhibitor	III	873	No improvement in overall survival [57]
Lenalidomide	Multiple mechanisms, including inhibition of VEGF-induced PI3K-Akt pathway signalling	I/II	60	Disease stabilisation, decrease in PSA [58]
		III	1059	Worse overall survival [59]

Aflibercept (a hybrid protein composed of various domains of VEGF-receptors 1 and 2, fused to human immunoglobulin G1) also targets the VEGF-A pathway, by acting as a decoy receptor for VEGF-A. Unfortunately, similar to bevacizumab, in a phase III multicentre, randomized double-blind placebo-controlled parallel group study in 1224 men with castration-resistant refractory tumors, aflibercept therapy combined with docetaxel chemotherapy and hormonal therapy did not show any improvement in overall survival [56].

Sunitinib and cediranib are small multireceptor molecule tyrosine kinase inhibitors, with a demonstrated activity against VEGF-receptors 1 and 2. Sunitinib is approved for the treatment of gastrointestinal stromal tumor, renal cell carcinoma and pancreatic neuroendocrine tumors. However, in a randomized, placebo-controlled, phase III trial of sunitinib therapy combined with hormonal therapy in 873 patients with refractory castration-resistant prostate cancer, there was no improvement in overall survival compared to placebo [57].

Furthermore, these anti-VEGF-A therapies have been associated with an increased rate of toxicity and adverse effects, resulting in the discontinuation of treatment (27% vs. 7%) [57]. These toxic and adverse effects included fatigue, asthenia, hand-foot syndrome, hypertension, bowel perforation, pulmonary thromboembolism, and gastrointestinal bleeding, seen in both pre-clinical and clinical studies [60,61]. In addition, treatment-related haematological problems also emerged in up to 20% of the patients, including lymphopenia, neutropenia, and anaemia [57].

Thalidomide is an immune-modulatory drug, which also has anti-angiogenic effects. Lenalidomide is a more potent analogue of thalidomide, with less prominent side effects. The mechanism of the anti-angiogenic effect of lenalidomide is not entirely elucidated, but appears to be through multiple mechanisms, including inhibition of VEGF-induced phosphatidylinositol-3,4,5-trisphosphate (PI3K)-Akt

pathway signalling [62]. Lenalidomide therapy in non-metastatic prostate cancer in a phase I/II double-blinded, randomized study of 60 patients resulted in stabilization of the disease and a decline in PSA, with minimal toxicity [58]. A randomized, double-blind, placebo-controlled phase III trial in 1059 patients with castration-resistant refractory prostate cancer, however showed worse overall survival when lenalidomide was added to prednisone, hormonal, and docetaxel chemotherapy, compared to the placebo group [59]. There was also a 25% increase in adverse events, which included haematological side effects (34% vs. 20%), diarrhoea (7% vs. 2%), pulmonary embolism (6% vs. 1%), and asthenia (5% vs. 3%) [59].

To summarize, these findings suggest that anti-angiogenic therapy has no clinical benefit when added to chemotherapy or hormonal therapy in refractory, castration-resistant prostate cancer.

4. Discussion

Clinical trials that showed an association between high VEGF-A expression and tumor progression assessed VEGF-A protein levels by immunohistochemistry, ELISA methods, or mRNA levels by reverse-transcription-polymerase chain reaction (RT-PCR). Despite high VEGF-A expression in advanced prostate cancer using these methods, anti-angiogenic therapies targeting the VEGF-A pathway have failed to provide significant treatment benefits [63,64]. There are various possible explanations for resistance to anti-angiogenic therapy in prostate cancer. Redundancy of angiogenic pathways means that targeting a single pathway may result in upregulation of alternative pathways. For example, with long-term bevacizumab treatment, which blocks VEGF-A, there is upregulation of EGF, HGF, and PDGF [65]. Lindholm et al. demonstrated in breast cancer xenografts that targeting these pathways can be effective in anti-angiogenic therapy [66]. A combination of different anti-angiogenic therapies in prostate cancer has also showed some promising results: a phase II study of combined bevacizumab and lenalidomide therapy, added to docetaxel and prednisone chemotherapy and hormonal therapy in 63 patients with metastatic castration-resistant prostate cancer found that combined anti-angiogenic therapy can be safely administered, but further randomized trials are required to confirm clinical benefit [67].

Another reason for treatment resistance is due to the fact that prostate cancer is a molecularly heterogeneous disease, and there is currently a lack of biomarkers that can help select those patients who are likely to benefit from anti-angiogenic therapy or that can assess response to anti-angiogenic treatment [48]. The genetic signature of the VEGF-A pathway or variations in VEGF-A or its receptors could be possible markers to predict therapy response, but these have as yet not been validated [68,69]. It is hoped that further stage III trials will be able to identify subgroups of patients who could benefit from anti-angiogenic treatment.

Resistance to sunitinib tyrosine-kinase-inhibitor has been shown to be associated with loss of the tumor suppressor protein phosphatase and tensin homolog (PTEN). PTEN is a gatekeeper protein that negatively regulates intracellular levels of PI3K and consequently suppresses the PI3K-Akt pathway, which normally promotes cell survival and growth [70]. Reinstating PTEN activity, by suppression of the PI3K-Akt pathway in *in vitro* studies, has been shown to restore sensitivity to sunitinib in cancer cells [70]. Loss of PTEN activity is considered a key event in prostate carcinogenesis, and reinstating PTEN activity in prostate cancer seems to be a promising tool in overcoming sunitinib resistance. In addition, activation of the PI3K-Akt pathway in tumors with PTEN deletion has been shown to be associated with repressed androgen signalling in prostate cancer, while suppression of the PI3K-Akt pathway was demonstrated to activate androgen receptor signalling [71,72]. In a similar way, suppression of the androgen signaling pathway resulted in activation of the PI3K-Akt pathway [71]. This suggests that there is a cross-talk between the androgen receptor and PI3K-Akt pathways, which would at least in part explain the castration-resistant phenotype observed in tumors with PTEN deletion. Since activation of the PI3K-Akt pathway appears to play an important role in resistance to both sunitinib and anti-androgenic therapy, suppression of the PI3K-Akt pathway could help overcome difficulties in anti-angiogenic and anti-androgenic therapy. Recent preclinical studies

on mouse models have shown that targeted inhibition of the PI3K-Akt pathway in castration-resistant prostate cancer resulted in both inhibited cancer cell proliferation and MVD [73,74]. Suboptimal results with bevacizumab treatment may also relate to the interaction between the androgen receptor (AR) signalling and angiogenic pathways. It has been long established that androgens upregulate VEGF-A expression [75], although the mechanism of this is not entirely understood [76]. Most recently, an interaction between epigenetic factors (Lysine specific demethylase 1 (LSD1), protein arginine methyltransferase 5 (PRMT5)) [77,78], zinc-finger transcription factors (specificity protein 1 (Sp1), Wilms tumor gene 1 (WT1), and early growth factor 1 (EGR1)) [76,79], different AR splice variants [80] and hypoxia mediated by the hypoxia-inducible factor 1 α (HIF-1 α) [81] have emerged as potential mechanisms for androgen-dependent VEGF-A regulation. Furthermore, AR has been shown to regulate EGFR expression in prostate cancer cells. [82,83] In addition to the role of EGFR in indirect angiogenesis promotion through interleukin production, [39] it has also been demonstrated to upregulate VEGF-A directly and through induction of HIF-1 α [84,85] (Figure 2).




Figure 2. Interaction between angiogenic and androgen receptor pathways in prostate cancer cells. Castration results in androgen depletion which causes hypoxia. Hypoxia enhances the transcriptional activity of androgen receptor (AR) at low androgen levels, as seen in castration-resistant prostate cancer. The activated androgen receptor promotes the overexpression of vascular endothelial growth factor A (VEGF-A) through hypoxia-inducible factor 1 α (HIF-1 α) and (specificity protein 1 (Sp1) related mechanisms and also via regulation of epidermal growth factor receptor (EGFR) expression and upregulation of cytokines, mainly interleukin (IL)-6 [86].

The interaction and the importance of angiogenesis and hormonal therapy in tumor progression have initiated a clinical trial implementing dual targeting of angiogenesis and androgen signalling in hormone-sensitive tumors [54]. As discussed above, this phase II clinical trial, which combined short-course androgen deprivation therapy with bevacizumab, improved relapse free survival in recurrent, hormone-sensitive tumors. In addition, it has been demonstrated that androgen deprivation by castration, causes hypoxia in prostatic tumor cells [87,88]. Hypoxia consequently enhances the transcriptional activity of AR in prostatic tumor cells at low androgen levels, such as seen

in castration-resistant prostate cancer [89]. It has been suggested that the activation of AR in hypoxic conditions is HIF-1 α mediated [90], hence targeting HIF-1 α could influence the AR stimulatory effect of hypoxia in castration-resistant prostate cancer. Recently, dual targeting of HIF-1 α and AR pathways by HIF-1 α inhibitors and enzalutamide, a second generation AR inhibitor, showed synergistic effect in castration-resistant prostate cancer cell lines, also resulting in decreased VEGF-A levels [81]. In addition, suppression of Sp1 binding to VEGF-A promoter resulted in significant reduction of VEGF-A level in castration-resistant prostate cancer cells [79]. However, a better understanding of the mechanism of the interaction between VEGF-A and AR is still needed to identify those patients who may benefit from dual targeting therapy [79,86].

Targeting VEGF-A also raises a further question: does inhibition of VEGF-A result in a pure anti-angiogenic effect? Interestingly, it has been shown that VEGF-A has different splice isoforms and these different isoforms can show pro- or anti-angiogenic functions [91]. In the terminal exon of the VEGF-A gene, there are two alternative splice sites. Splicing at the proximal splice site results in the canonical angiogenic VEGF_{165a} isoform. Splicing at the distal splice site results in an alternative splicing isoform VEGF_{165b}, which has been found to have anti-angiogenic effect by inhibiting vasodilation and reducing permeability [92,93]. The level of the anti-angiogenic VEGF_{165b} splice variant has also been found to be decreased in cancer cells, compared to normal tissue cells [93]. This means that, in cancer cells, there appears to be a shift towards the pro-angiogenic VEGF_{165a} splice variant at the expense of the anti-angiogenic VEGF_{165b} splice variant. The cause of this shift has not been entirely elucidated, but nuclear receptor-coregulator complexes have been shown to regulate splicing events, therefore aberrant recruitment of nuclear receptor-coregulator complexes to the VEGF promoter to promote VEGF_{165a} splicing has been suggested as a possible explanation [48,94]. Current anti-VEGF-A therapies lack isoform specificity, as the epitope of bevacizumab binds the N-terminal region of VEGF-A, which is present in all splice isoforms [95]. Thus, current anti-angiogenic therapies targeting VEGF-A function may result in both inhibition and promotion of tumor angiogenesis. However, the fact that the two isoforms appear to have different splice sites and post-translational regulation offers the possibility of selectively targeting specific isoforms. Serine-arginine protein kinase 1 (SRPK1), a kinase that phosphorylates SR-protein, appears to stimulate VEGF_{165a} splicing, whilst VEGF_{165b} splicing has been shown to be stimulated by Clk1/4, a dual specific protein kinase [96–98]. Investigation with SRPK1 knocked-down cell lines showed a shift towards the anti-angiogenic VEGF_{165b} isoform, while xenografts showed decreased tumor growth and decreased MVD in tumors [99]. In addition, specific inhibition of SRPK1 in a mouse tumor model has been shown to be associated with reduced tumor growth [100] (Figure 3).

Most current mainstream anti-angiogenic treatment therapies focus on direct angiogenesis inhibition. A further possible treatment option is indirect inhibition of angiogenesis, targeting an interplay between tumor or stromal cells and angiogenesis. The galectin family of proteins have emerged as playing an important role in this interplay, facilitating tumor progression. Galectins are β -galactoside-binding lectin proteins, which are overexpressed in various cancers and have been associated with poor prognosis and tumor progression in prostate cancer [101]. In addition to their intracellular function of promoting cell transformation and survival, galectins are also secreted into the extracellular space. Here they interact with cell surface receptors, resulting in suppression of the immune response and promotion of angiogenesis, likely by means of interaction with VEGF-receptor2 [102,103]. Rabinovich and colleagues identified that prostate cancer shows a unique galectin expression profile during cancer progression, and showed that galectin-1 is uniquely expressed at high levels in advanced prostate cancer [104]. This makes galectin-1 a potential target of angiogenesis therapy in advanced prostate cancer [105].




Figure 3. Alternative splicing of VEGF-A. Splicing at the proximal splicing site (PSS) is stimulated by serine-arginine protein kinase 1 (SRPK1), and results in the pro-angiogenic VEGF_{165a} splice variant. Clk1/4 stimulates splicing at the distal splicing site (DSS), which results in the anti-angiogenic VEGF_{165b} isoform.

5. Materials and Methods

The literature review was conducted by a Pubmed literature search engine using a collection of keywords with no restriction on publication date. The following word strings were used as keywords: “angiogenesis”[All Fields] AND [“prostatic neoplasms”[MeSH Terms] OR [“prostatic”[All Fields] AND “neoplasms”[All Fields]] OR “prostatic neoplasms”[All Fields] OR [“prostate”[All Fields] AND “cancer”[All Fields]] OR “prostate cancer”[All Fields]. The search results were subsequently filtered by article type, specifically clinical trials and review articles. Abstracts were assessed for relevance with subsequent review of full text versions. Only phase II or III studies were included. Studies cited by these articles, but not included in the algorithm, were also manually scoped and were also subject of the review.

6. Conclusions

The association of MVD and overexpression of VEGF-A with tumor prognosis in prostate cancer suggested that angiogenesis has an important role in prostate cancer progression. Supplementation of hormonal manipulation and chemotherapy with anti-angiogenesis therapy in hormone-sensitive prostate cancer showed some positive effect, further supporting the hypothesis that angiogenesis is an important factor in prostate cancer. Despite this, clinical trials in refractory castration-resistant prostate cancer hitherto have shown increased toxicity with no clinical benefit. A better understanding of the mechanism of angiogenesis may help to understand the failure of trials, possibly leading to targeted anti-angiogenic therapies in prostate cancer. These could include identification of specific subgroups of patients who might benefit from therapies, targeting tumor-suppressor genes that play a role in treatment resistance, or by identifying and selectively targeting splice variants of VEGF-A.

Funding: Funding for this study was supported by grants from British Heart Foundation to SO (PG/15/53/31371), Diabetes UK to SO (17/0005668).

Acknowledgments: We wish to acknowledge Cornelia Szecsei for her critical reading of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest

References

1. National Cancer Institute. *SEER Stat Fact Sheets: Prostate*; National Cancer Institute: Bethesda, MD, USA. Available online: <https://seer.cancer.gov/statfacts/html/prost.html#prevalence> (accessed on 10 March 2018).

2. American Cancer Society. *Cancer Facts and Figures*; American Cancer Society: Atlanta, GA, USA, 2018; Available online: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf> (accessed on 10 March 2018).
3. Cancer Research UK. Prostate Cancer Incidence Statistics [Internet]. 2014. Available online: <http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/#age> (accessed on 14 August 2018).
4. Zlotta, A.R.; Egawa, S.; Pushkar, D.; Govorov, A.; Kimura, T.; Kido, M.; Takahashi, H.; Kuk, C.; Kovylyna, M.; Aldaoud, N.; et al. Prevalence of prostate cancer on autopsy: Cross-sectional study on unscreened Caucasian and Asian men. *J. Natl. Cancer Inst.* **2013**, *105*, 1050–1058. [[CrossRef](#)] [[PubMed](#)]
5. American Cancer Society. *Cancer Facts and Figures*; American Cancer Society: Atlanta, GA, USA, 2012; Available online: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2012/estimated-number-of-new-cancer-cases-and-deaths-by-sex-2012.pdf> (accessed on 19 August 2018).
6. The National Cancer Registration Service, Eastern Office [Internet]. Available online: <http://www.ncras.nhs.uk/ncrs-east/> (accessed on 14 August 2018).
7. Zelefsky, M.J.; Eastham, J.A.; Sartor, A.O. Cancer of the prostate. In *Cancer: Principles and Practice of Oncology*, 9th ed.; De Vita, V.T., Jr., Lawrence, T.S., Rosenberg, S.A., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2011; pp. 1220–7121.
8. PDQ Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ[®]): Patient Version. 30 April 2018. In *PDQ Cancer Information Summaries [Internet]*; National Cancer Institute (US): Bethesda, MD, USA, 2002. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK65915/> (accessed on 19 August 2018).
9. Hamdy, F.C.; Donovan, J.L.; Lane, J.A.; Mason, M.; Metcalfe, C.; Holding, P.; Davis, M.; Peters, T.J.; Turner, E.L.; Martin, R.M.; et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. *N. Engl. J. Med.* **2016**, *375*, 1415–1424. [[CrossRef](#)] [[PubMed](#)]
10. Graham, J.; Kirkbride, P.; Cann, K.; Hasler, E.; Prettyjohns, M. Prostate cancer: summary of updated NICE guidance. *BMJ* **2014**, *8*, 348. [[CrossRef](#)]
11. Ragde, H.; Blasko, J.C.; Grimm, P.D.; Kenny, G.M.; Sylvester, J.E.; Hoak, D.C.; Landin, K.; Cavanagh, W. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. *Cancer* **1997**, *80*, 442–453. [[CrossRef](#)]
12. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. *Br. J. Urol.* **1997**, *79*, 235–426.
13. Dearnaley, D.P.; Mason, M.D.; Parmar, M.K.; Sanders, K.; Sydes, M.R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomized controlled trials. *Lancet Oncol.* **2009**, *10*, 872–876. [[CrossRef](#)]
14. James, N.D.; de Bono, J.S.; Spears, M.R.; Clarke, N.W.; Mason, M.D.; Dearnaley, D.P.; Ritchie, A.W.; Amos, C.L.; Gilson, C.; Jones, R.J. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *N. Engl. J. Med.* **2017**, *377*, 338–351. [[CrossRef](#)]
15. Scher, H.I.; Fizazi, K.; Saad, F.; Taplin, M.E.; Sternberg, C.N.; Miller, K.; de Wit, R.; Mulders, P.; Chi, K.N.; Shore, N.D.; et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N. Engl. J. Med.* **2012**, *367*, 1187–1197. [[CrossRef](#)]
16. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N. Engl. J. Med.* **2010**, *363*, 411–422. [[CrossRef](#)]
17. Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S.I.; O’sullivan, J.M.; Fosså, S.D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N. Engl. J. Med.* **2013**, *369*, 213–223. [[CrossRef](#)]
18. De Bono, J.S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, L.; et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. *Lancet* **2010**, *376*, 1147–1154. [[CrossRef](#)]
19. Fizazi, K.; Carducci, M.; Smith, M.; Damião, R.; Brown, J.; Karsh, L.; Milecki, P.; Shore, N.; Rader, M.; Wang, H.; et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomized, double-blind study. *Lancet* **2011**, *377*, 813–822. [[CrossRef](#)]

20. Oosterhof, G.O.N.; Roberts, J.T.; de Reijke, T.M.; Engelholm, S.A.; Horenblas, S.; von der Maase, H.; Neymark, N.; Debois, M. ColletteL. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. *Eur. Urol.* **2003**, *44*, 519–526. [[CrossRef](#)]
21. Fizazi, K.; Tran, N.; Fein, L.; Matsubara, N.; Rodriguez-Antolin, A.; Alekseev, B.Y.; Özgüroğlu, M.; Ye, D.; Feyerabend, S.; Protheroe, A.; et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *N. Engl. J. Med.* **2017**, *377*, 352–360. [[CrossRef](#)]
22. Rajabi, M.; Mousa, S.A. The Role of Angiogenesis in Cancer Treatment. *Biomedicines* **2017**, *21*, 34. [[CrossRef](#)]
23. Winkler, F. Hostile takeover: How tumors hijack pre-existing vascular environments to thrive. *J. Pathol.* **2017**, *242*, 267–272. [[CrossRef](#)]
24. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. *Cell* **2011**, *144*, 646–674. [[CrossRef](#)]
25. Pavlakovic, H.; Havers, W.; Schweigerer, L. Multiple angiogenesis stimulators in a single malignancy: Implications for anti-angiogenic tumor therapy. *Angiogenesis* **2001**, *4*, 259–262. [[CrossRef](#)]
26. Kerbel, R.S. Tumor angiogenesis. *N. Engl. J. Med.* **2008**, *358*, 2039–2049. [[CrossRef](#)]
27. Gressett, M.; Shah, S.R. Intracacies of bevacizumab-induced toxicities and their management. *Ann. Pharmacother.* **2009**, *43*, 490–501. [[CrossRef](#)]
28. Kamba, T.; McDonald, D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. *Br. J. Cancer* **2007**, *96*, 1788–1795. [[CrossRef](#)]
29. Ferrara, N. VEGF as a therapeutic target in cancer. *Oncology* **2005**, *69* (Suppl. 3), 11–16. [[CrossRef](#)] [[PubMed](#)]
30. Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. *Nature* **2011**, *473*, 298–307. [[CrossRef](#)]
31. El-Kenawi, A.E.; El-Remessy, A.B. Angiogenesis inhibitors in cancer therapy: Mechanistic perspective on classification and treatment rationales. *Br. J. Pharmacol.* **2013**, *170*, 712–729. [[CrossRef](#)]
32. Mundel, T.M.; Kalluri, R. Type IV collagen-derived angiogenesis inhibitors. *Microvasc. Res.* **2007**, *74*, 85–89. [[CrossRef](#)]
33. Kurozumi, K.; Ichikawa, T.; Onishi, M.; Fujii, K.; Date, I. Cilengitide treatment for malignant glioma: Current status and future direction. *Neurol. Med. Chir.* **2012**, *52*, 539–547. [[CrossRef](#)]
34. Su, J.; Cai, M.; Li, W.; Hou, B.; He, H.; Ling, C.; Huang, T.; Liu, H.; Guo, Y. Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review. *Oncol. Res.* **2016**, *24*, 117–128. [[CrossRef](#)] [[PubMed](#)]
35. Herbert, S.P.; Stainier, D.Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. *Nat. Rev. Mol. Cell. Biol.* **2011**, *12*, 551–564. [[CrossRef](#)] [[PubMed](#)]
36. Margolin, K.; Gordon, M.S.; Holmgren, E.; Gaudreault, J.; Novotny, W.; Fyfe, G.; Adelman, D.; Stalter, S.; Breed, J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. *J. Clin. Oncol.* **2011**, *19*, 851–856. [[CrossRef](#)]
37. Ferrara, N.; Adamis, A.P. Ten years of anti-vascular endothelial growth factor therapy. *Nat. Rev. Drug Discov.* **2016**, *15*, 385–403. [[CrossRef](#)]
38. Li, M.; Kroetz, D.L. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. *Pharmacol. Ther.* **2018**, *182*, 152–160. [[CrossRef](#)]
39. Minder, P.; Zajac, E.; Quigley, J.P.; Deryugina, E.I. EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation. *Neoplasia* **2015**, *17*, 634–649. [[CrossRef](#)]
40. Sharma, S.; Sharma, M.C.; Sarkar, C. Morphology of angiogenesis in human cancer: A conceptual overview, histoprognostic perspective and significance of neoangiogenesis. *Histopathology* **2005**, *46*, 481–489. [[CrossRef](#)]
41. Bono, A.V.; Celato, N.; Cova, V.; Salvatore, M.; Chinetti, S.; Novario, R. Microvessel density in prostate carcinoma. *Prostate Cancer Prostatic Dis.* **2002**, *5*, 123–127. [[CrossRef](#)]
42. Borre, M.; Offersen, B.V.; Nerstrom, B.; Overgaard, J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. *Br. J. Cancer* **1998**, *78*, 940–944. [[CrossRef](#)]
43. Jiang, J.; Chen, Y.; Zhu, Y.; Yao, X.; Qi, J. Contrast-enhanced ultrasonography for the detection and characterization of prostate cancer: Correlation with microvessel density and Gleason score. *Clin. Radiol.* **2011**, *66*, 732–737. [[CrossRef](#)]

44. Tretiakova, M.; Antic, T.; Binder, D.; Kocherginsky, M.; Liao, C.; Taxy, J.B.; Oto, A. Microvessel density is not increased in prostate cancer: Digital imaging of routine sections and tissue microarrays. *Hum. Pathol.* **2013**, *44*, 495–502. [[CrossRef](#)] [[PubMed](#)]
45. Miyata, Y.; Saka, H. Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: Usefulness and limitations of microvessel density measurement. *Int. J. Urol.* **2015**, *22*, 806–815. [[CrossRef](#)] [[PubMed](#)]
46. Taverna, G.; Grizzi, F.; Colombo, P.; Seveso, M.; Giusti, G.; Proietti, S.; Fiorini, G.; Lughezzani, G.; Casale, P.; Buffi, N.; et al. Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer. *Korean J. Urol.* **2015**, *56*, 435–442. [[CrossRef](#)] [[PubMed](#)]
47. Taverna, G.; Grizzi, F.; Colombo, P.; Graziotti, P. Is angiogenesis a hallmark of prostate cancer? *Front. Oncol.* **2013**, *3*, 15. [[CrossRef](#)] [[PubMed](#)]
48. De Brot, S.; Ntekim, A.; Cardenas, R.; James, V.; Allegrucci, C.; Heery, D.M.; Bates, D.O.; Ødum, N.; Persson, J.L.; Mongan, N.P. Regulation of vascular endothelial growth factor in prostate cancer. *Endocr. Relat. Cancer* **2015**, *22*, 107–123. [[CrossRef](#)]
49. Wong, S.Y.; Haack, H.; Crowley, D.; Barry, M.; Bronson, R.T.; Hynes, R.O. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. *Cancer Res.* **2005**, *65*, 9789–9798. [[CrossRef](#)]
50. Wegiel, B.; Bjartell, A.; Ekberg, J.; Gadaleanu, V.; Brunhoff, C.; Persson, J.L. A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. *Oncogene* **2005**, *24*, 6385–6393. [[CrossRef](#)]
51. Green, M.M.; Hiley, C.T.; Shanks, J.H.; Bottomley, I.C.; West, C.M.; Cowan, R.A.; Stratford, I.J. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. *Int. J. Radiat. Oncol. Biol. Phys.* **2007**, *67*, 84–90. [[CrossRef](#)]
52. Duque, J.L.; Loughlin, K.R.; Adam, R.M.; Kantoff, P.W.; Zurakowski, D.; Freeman, M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. *Urology* **1999**, *54*, 523–527. [[CrossRef](#)]
53. Hrouda, D.; Nicol, D.L.; Gardiner, R.A. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. *Urol. Res.* **2003**, *30*, 347–355.
54. McKay, R.R.; Zurita, A.J.; Werner, L.; Bruce, J.Y.; Carducci, M.A.; Stein, M.N.; Heath, E.I.; Hussain, A.; Tran, H.T.; Sweeney, C.J.; et al. Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. *J. Clin. Oncol.* **2016**, *34*, 1913–1920. [[CrossRef](#)]
55. Kelly, W.K.; Halabi, S.; Carducci, M.; George, D.; Mahoney, J.F.; Stadler, W.M.; Morris, M.; Kantoff, P.; Monk, J.P.; Kaplan, E.; et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. *J. Clin. Oncol.* **2012**, *30*, 1534–1540. [[CrossRef](#)]
56. Tannock, I.F.; Fizazi, K.; Ivanov, S.; Karlsson, C.T.; Fléchon, A.; Skoneczna, I.; Orlandi, F.; Gravis, G.; Matveev, V.; Bavbek, S.; et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomized trial. *Lancet Oncol.* **2013**, *14*, 760–768. [[CrossRef](#)]
57. Michaelson, M.D.; Oudard, S.; Ou, Y.C.; Sengeløv, L.; Saad, F.; Houede, N.; Ostler, P.; Stenzl, A.; Daugaard, G.; Jones, R.; et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. *J. Clin. Oncol.* **2014**, *32*, 76–82. [[CrossRef](#)]
58. Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: Results of a phase I/II double-blinded, randomized study. *Clin. Cancer Res.* **2010**, *16*, 5269–5276. [[CrossRef](#)]
59. Petrylak, D.P.; Vogelzang, N.J.; Budnik, N.; Wiechno, P.J.; Sternberg, C.N.; Doner, K.; Bellmunt, J.; Burke, J.M.; de Olza, M.O.; Choudhury, A.; et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomized, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol.* **2015**, *16*, 417–425. [[CrossRef](#)]
60. Mangoni, M.; Vozenin, M.C.; Biti, G.; Deutsch, E. Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: Hurdles might be ahead. *Br. J. Cancer* **2012**, *107*, 308–314. [[CrossRef](#)] [[PubMed](#)]

61. Ogita, S.; Tejwani, S.; Heilbrun, L.; Fontana, J.; Heath, E.; Freeman, S.; Smith, D.; Baranowski, K.; Vaishampayan, U. Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. *ISRN Oncol.* **2012**, *2012*, 242850. [[CrossRef](#)] [[PubMed](#)]
62. Ribatti, D.; Vacca, A. New Insights in Anti-Angiogenesis in Multiple Myeloma. *Int. J. Mol. Sci.* **2018**, *19*, 2031. [[CrossRef](#)] [[PubMed](#)]
63. Liu, Z.-Q.; Fang, J.-M.; Xiao, Y.-Y.; Zhao, Y.; Cui, R.; Hu, F.; Xu, Q. Prognostic role of vascular endothelial growth factor in prostate cancer: A systematic review and meta-analysis. *Int. J. Clin. Exp. Med.* **2015**, *8*, 2289–2298. [[PubMed](#)]
64. Wang, K.; Peng, H.L.; Li, L.K. Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: A systematic review with meta-analysis. *Asian Pac. J. Cancer Prev.* **2012**, *13*, 5665–5669. [[CrossRef](#)] [[PubMed](#)]
65. Scholz, A.; Harter, P.N.; Cremer, S.; Yalcin, B.H.; Gurnik, S.; Yamaji, M.; Di Tacchio, M.; Sommer, K.; Baumgarten, P.; Bähr, O.; et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. *EMBO Mol. Med.* **2016**, *8*, 39–57. [[CrossRef](#)]
66. Lindholm, E.M.; Krohn, M.; Iadevaia, S.; Kristian, A.; Mills, G.B.; Mælandsmo, G.M.; Engebraaten, O. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. *Clin. Cancer Res.* **2014**, *20*, 404–412. [[CrossRef](#)]
67. Madan, R.A.; Karzai, F.H.; Ning, Y.-M.; Adesunloye, B.A.; Huang, X.; Harold, N.; Couvillon, A.; Chun, G.; Cordes, L.; Sissung, T.; et al. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. *BJU Int.* **2016**, *118*, 590–597. [[CrossRef](#)]
68. Brauer, M.J.; Zhuang, G.; Schmidt, M.; Yao, J.; Wu, X.; Kaminker, J.S.; Jurinka, S.S.; Kolumam, G.; Chung, A.S.; Jubb, A.; et al. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. *Clin. Cancer Res.* **2013**, *19*, 3681–3692. [[CrossRef](#)]
69. De Haas, S.; Delmar, P.; Bansal, A.T.; Moisse, M.; Miles, D.W.; Leighl, N.; Escudier, B.; Van Cutsem, E.; Carmeliet, P.; Scherer, S.J.; et al. Genetic variability of VEGF pathway genes in six randomized Phase III trials assessing the addition of bevacizumab to standard therapy. *Angiogenesis* **2014**, *17*, 909–920. [[CrossRef](#)]
70. Golovine, K.; Kutikov, A.; Teper, E.; Simhan, J.; Makhov, P.B.; Canter, D.J.; Uzzo, R.G.; Kolenko, V.M. Modulation of Akt/mTOR signalling overcomes sunitinib resistance in renal and prostate cancer cells. *Mol. Cancer Ther.* **2012**, *11*, 1510–1517.
71. Carver, B.S.; Chapinski, C.; Wongvipat, J.; Hieronymus, H.; Chen, Y.; Chandarlapaty, S.; Arora, V.K.; Le, C.; Koutcher, J.; Scher, H.; et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. *Cancer Cell* **2011**, *19*, 575–586. [[CrossRef](#)]
72. Wang, Y.; Kreisberg, J.L.; Ghosh, P.M. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. *Curr. Cancer Drug Targets* **2007**, *7*, 591–604. [[CrossRef](#)]
73. Yamamoto, Y.; A De Velasco, M.; Kura, Y.; Nozawa, M.; Hatanaka, Y.; Oki, T.; Ozeki, T.; Shimizu, N.; Minami, T.; Yoshimura, K.; et al. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. *J. Transl. Med.* **2015**, *13*, 150. [[CrossRef](#)]
74. De Velasco, M.A.; Kura, Y.; Yoshikawa, K.; Nishio, K.; Davies, B.R.; Uemura, H. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. *Oncotarget* **2016**, *7*, 15959–15976. [[CrossRef](#)]
75. Sordello, S.; Bertrand, N.; Plouet, J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. *Biochem. Biophys. Res. Commun.* **1998**, *251*, 287–290. [[CrossRef](#)]
76. Eisermann, K.; Fraizer, G. The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer. *Cancers* **2017**, *9*, 32. [[CrossRef](#)]
77. Kashyap, V.; Ahmad, S.; Nilsson, E.M.; Helczynski, L.; Kenna, S.; Persson, J.L.; Gudas, L.J.; Mongan, N.P. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. *Mol. Oncol.* **2013**, *7*, 555–566. [[CrossRef](#)]
78. Deng, X.; Shao, G.; Zhang, H.; Li, C.; Zhang, D.; Cheng, L.; Elzey, B.; Pili, R.; Ratliff, T.; Huang, J. Proteinarginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. *Oncogene* **2016**, *36*, 1223–1231. [[CrossRef](#)]
79. Eisermann, K.; Broderick, C.J.; Bazarov, A.; Moazam, M.M.; Fraizer, G.C. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. *Mol. Cancer* **2013**, *12*, 7. [[CrossRef](#)]

80. Antonarakis, E.; Armstrong, A.; Dehm, S.; Luo, J. Androgen receptor variant-driven prostate cancer: Clinical implications and therapeutic targeting. *Prostate Cancer Prostatic Dis.* **2016**, *19*, 231–241. [[CrossRef](#)]
81. Fernandez, E.V.; Reece, K.M.; Ley, A.M.; Troutman, S.M.; Sissung, T.M.; Price, D.K.; Chau, C.H.; Figg, W.D. Dual targeting of the androgen receptor and hypoxia-inducible factor 1 α pathways synergistically inhibits castration-resistant prostate cancer cells. *Mol. Pharmacol.* **2015**, *87*, 1006–1012. [[CrossRef](#)]
82. Pignon, J.C.; Koopmansch, B.; Nolens, G.; Delacroix, L.; Waltregny, D.; Winkler, R. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. *Cancer Res.* **2009**, *69*, 2941–2949. [[CrossRef](#)]
83. Zheng, Y.; Izumi, K.; Yao, J.L.; Miyamoto, H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. *Endocr. Relat. Cancer* **2011**, *18*, 451–464. [[CrossRef](#)]
84. Taberero, J. The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. *Mol. Cancer Res.* **2007**, *5*, 203–220. [[CrossRef](#)]
85. Mabeesh, N.J.; Willard, M.T.; Frederickson, C.E.; Zhong, H.; Simons, J.W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. *Clin. Cancer Res.* **2003**, *9*, 2416–2425.
86. Cereda, V.; Formica, V.; Roselli, M. Issues and promises of bevacizumab in prostate cancer treatment. *Exp. Opin. Biol. Ther.* **2018**, *18*, 707–717. [[CrossRef](#)]
87. Shabsigh, A.; Ghafar, M.A.; De La Taille, A.; Burchardt, M.; Kaplan, S.A.; Anastasiadis, A.G.; Buttyan, R. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. *J. Cell Biochem.* **2001**, *81*, 437–444. [[CrossRef](#)]
88. Halin, S.; Hammarsten, P.; Wikström, P.; Bergh, A. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. *Prostate* **2007**, *67*, 370–377. [[CrossRef](#)]
89. Mitani, T.; Harada, N.; Nakano, Y.; Inui, H.; Yamaji, R. Coordinated action of hypoxia-inducible factor-1 α and β -catenin in androgen receptor signaling. *J. Biol. Chem.* **2012**, *287*, 33594–33606. [[CrossRef](#)]
90. Horii, K.; Suzuki, Y.; Kondo, Y.; Akimoto, M.; Nishimura, T.; Yamabe, Y.; Sakaue, M.; Sano, T.; Kitagawa, T.; Himeno, S.; et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. *Mol. Cancer Res.* **2007**, *5*, 383–391. [[CrossRef](#)]
91. Bates, D.; Cui, T.-G.; Doughty, J.M.; Winkler, M.; Sugiono, M.; Shields, J.D.; Peat, D.; Gillatt, D.; Harper, S.J. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. *Cancer Res.* **2002**, *62*, 4123–4131.
92. Woolard, J.; Wang, W.Y.; Bevan, H.S.; Qiu, Y.; Morbidelli, L.; Pritchard-Jones, R.O.; Cui, T.G.; Sugiono, M.; Waive, E.; Perrin, R.; et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. *Cancer Res.* **2004**, *64*, 7822–7835. [[CrossRef](#)]
93. Oltean, S.; Gammons, M.; Hulse, R.; Hamdollah-Zadeh, M.; Mavrou, A.; Donaldson, L.; Salmon, A.H.; Harper, S.J.; Lodomery, M.R.; Bates, D.O. SRPK1 inhibition in vivo: Modulation of VEGF splicing and potential treatment for multiple diseases. *Biochem. Soc. Trans.* **2012**, *40*, 831–835. [[CrossRef](#)]
94. Auboeuf, D.; Dowhan, D.H.; Kang, Y.K.; Larkin, K.; Lee, J.W.; Berget, S.M.; O'Malley, B.W. Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice site choice in target genes. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 2270–2274. [[CrossRef](#)]
95. Peach, C.J.; Mignone, V.W.; Arruda, M.A.; Alcobia, D.C.; Hill, S.J.; Kilpatrick, L.E.; Woolard, J. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. *Int. J. Mol. Sci.* **2018**, *19*, 1264. [[CrossRef](#)]
96. Amin, E.M.; Oltean, S.; Hua, J.; Gammons, M.V.; Hamdollah-Zadeh, M.; Welsh, G.I.; Cheung, M.-K.; Ni, L.; Kase, S.; Rennel, E.S.; et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. *Cancer Cell* **2011**, *20*, 768–780. [[CrossRef](#)]
97. Nowak, D.G.; Woolard, J.; Amin, E.M.; Konopatskaya, O.; Saleem, M.A.; Churchill, A.J.; Lodomery, M.R.; Harper, S.J.; Bates, D.O. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. *J. Cell Sci.* **2008**, *121*, 3487–3495. [[CrossRef](#)]

98. Nowak, D.G.; Amin, E.M.; Rennel, E.S.; Hoareau-Aveilla, C.; Gammons, M.; Damodaran, G.; Hagiwara, M.; Harper, S.J.; Woolard, J.; Ladomery, M.R.; et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: A novel therapeutic strategy for angiogenesis. *J. Biol. Chem.* **2010**, *285*, 5532–5540. [[CrossRef](#)]
99. Mavrou, A.; Brakspear, K.; Hamdollah-Zadeh, M.; Damodaran, G.; Babaei-Jadidi, R.; Oxley, J.; Gillatt, D.A.; Ladomery, M.R.; Harper, S.J.; Bates, D.O.; Oltean, S. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. *Oncogene* **2015**, *34*, 4311–4319. [[CrossRef](#)] [[PubMed](#)]
100. Mavrou, A.; Oltean, S. SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing. *Pharmacol. Res.* **2016**, *107*, 276–281. [[CrossRef](#)]
101. Van den Brûle, F.A.; Waltregny, D.; Castronovo, V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. *J. Pathol.* **2001**, *193*, 80–87. [[CrossRef](#)]
102. Stanley, P. Galectin-1 Pulls the Strings on VEGFR2. *Cell* **2014**, *156*, 625–626. [[CrossRef](#)] [[PubMed](#)]
103. Jaworski, F.M.; Gentilini, L.D.; Gueron, G.; Meiss, R.P.; Ortiz, E.G.; Berguer, P.M.; Ahmed, A.; Navone, N.; Rabinovich, G.A.; Compagno, D.; et al. In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development. *Clin. Cancer Res.* **2017**, *23*, 5135–5148. [[CrossRef](#)] [[PubMed](#)]
104. Laderach, D.J.; Gentilini, L.D.; Giribaldi, L.; Delgado, V.C.; Nugnes, L.; Croci, D.O.; Al Nakouzi, N.; Sacca, P.; Casas, G.; Mazza, O.; et al. A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease. *Cancer Res.* **2013**, *73*, 86–96. [[CrossRef](#)] [[PubMed](#)]
105. Goud, N.S.; Soukya, P.S.L.; Ghose, M.; Komal, D.; Alvala, R.; Alvala, M. Human Galectin-1 and its inhibitors: Privileged target for cancer and HIV. *Mini Rev. Med. Chem.* **2019**. [[CrossRef](#)] [[PubMed](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).